Option Care Health Business Model Canvas

Contracting with commercial, Medicare (about 65 million enrollees in 2024), and Medicaid plans is core to driving covered access for Option Care Health. Aligning prior authorization and utilization management with payors reduces patient and clinician friction and denial rates. Value-based arrangements increasingly tie reimbursement to outcomes and total cost of care. PBM relationships—with PBMs handling roughly 80% of prescription claims—streamline specialty drug sourcing.

Key partnerships with prescribers, hospitals, payors, PBMs and manufacturers secure therapy access, optimize transitions of care and reduce readmissions (~25%) and inpatient costs (~40%). PBMs cover ~80% of claims; specialty drugs drive ~60% of US drug spend. Allied home-health and regional networks extend nationwide reach and boost persistence (+20%).

Discharge planners coordinate referrals, benefits verification, and scheduling to ensure timely home infusion starts, supporting Option Care Health’s rapid onboarding that industry data showed reduced post-discharge therapy gaps by 30% in 2024. Multidisciplinary teams align nursing, pharmacy, and prescriber actions to cut medication errors and delays. Focused patient education improves self-management and adherence, lowering readmission risk and total cost of care.

Option Care delivers over 2M home/alternate-site infusions annually with <1% serious events and ~98% reimbursement capture; USP 797/800 cleanrooms and lot-level tracking support sterility and supply continuity. Multidisciplinary discharge and benefits workflows cut post-discharge therapy gaps 30% and readmissions 20%, yielding ~$110M TCOC savings in 2024.

Payor network agreements secure patient access and rate stability for Option Care Health (NASDAQ: OPCH), supporting scale across home and alternate-site infusion; OPCH reported about $4.8 billion revenue in 2023, underscoring contract leverage. Accreditations (URAC/ACHC) signal quality and enable limited-distribution meds. Compliance assets reduce audit exposure and financial risk. Contract portfolios function as strategic assets in competitive payor markets.

Option Care Health leverages ~3,000 infusion-trained clinicians, USP 797/800 compounding sites, and payor contracts to deliver home and alternate-site infusion at scale with ~25% surge capacity.

Annual clinician competency >12 hours, cold-chain logistics, and integrated EHR/analytics (EHR adoption >95% in 2024) drive quality and operational efficiency.

Alternative-site infusion can lower site-of-care costs by up to 40% versus hospital outpatient settings (2023–24 studies), while evidence-driven protocols have cut 30-day readmissions by about 25% in real-world infusion programs. Predictable billing and coverage guidance reduce claim denials and patient cost surprises. With roughly 30 million Medicare Advantage enrollees in 2024, robust value reporting enables participation in risk-based and shared-savings models.

Option Care delivers high‑acuity infusion at home or alternate sites, cutting LOS by up to 40% and total costs up to 50% versus inpatient care (2024). A single integrated partner managed >1M encounters in 2024, reducing treatment delays ~20% and achieving therapy starts <48 hours. Adherence >85% with programs lowering missed doses up to 30% and 24/7 clinical support reducing escalations and 30‑day readmissions ~25%.

Account-managed payor partnerships sustain network performance through dedicated teams and 95% on-time delivery SLAs that define service expectations. Quarterly reviews align utilization and quality metrics with contractual KPIs, while collaborative pilots — in 2024 industry pilots — showed up to 10% total-cost reductions and measurable utilization improvements. These mechanisms support scalable value-based initiatives and payor confidence.

Option Care Health uses clinical co-management and shared data to align prescribers and patients, leveraging 2023 revenue of about $5.2B and serving ~250,000 patients in 2024. Dedicated care coordinators and 24/7 access reduce interruptions and acute escalations. Payor account teams maintain 95% on-time SLAs and pilots showed up to 10% TCO reduction.

Onsite Option Care teams facilitate bedside enrollment for timely transitions to home infusion, reducing inpatient burden. Education sessions for clinicians in 2024 inform care teams of capabilities and streamline referrals. Joint discharge protocols embed home infusion in care plans while co-branded materials improve patient acceptance; Option Care Health operates nationwide across all 50 states.

Physicians, discharge planners and in-network payer portals channel referrals to Option Care Health (2023 revenue $3.6B; >2.5M patients annually), with embedded liaisons and EMR integrations (Epic ~33% US hospital share) plus telehealth/digital intake cutting start-of-care by up to 30% and national coverage across all 50 states.

Hospitals aiming to shorten length of stay and prevent readmissions (U.S. 30-day readmission ≈15%) need partners to manage post-acute infusion safely. Value is measured in throughput, clinical quality metrics and patient experience scores. Seamless integration with discharge workflows and EHRs is critical to hit LOS and readmission targets while maintaining continuity of care.

Patients with chronic specialty needs, physicians, hospitals, payers/PBMs and self-funded employers prioritize safe, convenient, cost-effective home infusion and specialty pharmacy services. Option Care reduces clinic burden, supports site-of-care steering and value-based outcomes to improve adherence and lower total cost. Metrics drive contracting and care pathways.

Facility and equipment overhead for Option Care Health includes cleanroom construction and validation, continuous environmental monitoring and scheduled maintenance that create large fixed-cost bases; significant depreciation on specialized infusion and compounding equipment materially impacts operating expense; utilities and routine compliance testing are recurring line items; a broad geographic footprint raises lease and facility management expenses across markets.

Specialty biologics, limited-distribution drugs and sterile supplies drive COGS, with specialty therapies representing nearly half of U.S. drug spend (CMS 2022–2023). Labor (RN ~$39/hr, pharmacist ~$61/hr, May 2024) plus care coordination are largest OPEX. Cold-chain logistics (55–65% of logistics OPEX in 2024) and same-day delivery (2–3x cost) raise variable costs; facilities and compliance create large fixed costs.

Nursing and administration fees are billed per infusion visit for setup and monitoring, with 2024 per-visit reimbursements commonly falling in the $200–$500 range depending on therapy and payer. CPT and HCPCS procedure codes capture complexity and time, driving higher reimbursement for longer or complex infusions. After-hours and weekend services frequently carry premiums of 10–30% above base rates. Accurate documentation and coding remain essential to secure full payment.

Option Care Health revenues come from payer reimbursements (commercial, Medicare ≈65M beneficiaries in 2024, Medicaid), drug spreads (specialty ≈54% of US drug spend in 2024) and dispensing fees ($25–75), plus administration fees ($200–$500 per infusion) and value-based incentives; denials (~8–12%) and inventory/carrying costs compress margins.